The dilutive offering (~11% share count increase) is a near-term negative for existing shareholders, though the cash infusion supports the company's clinical pipeline. Monitor for any subsequent updates on NRX-100/NRX-101 regulatory progress, as the stock's prior strong performance (+35% avg T+20 alpha) suggests high sensitivity to pipeline catalysts.
Price Chart
Executive Summary
NRx Pharmaceuticals priced an underwritten public offering of 5,714,286 shares at $3.50/share, with gross proceeds of ~$20.0M ($23.0M if underwriters fully exercise the 30-day option). The offering is dilutive (~11% of pre-offering shares) and proceeds are for working capital and general corporate purposes. The stock closed at $3.50 on June 3, 2026, indicating no premium/discount at pricing.
Key Financial Metrics
Key Facts
- Pricing of 5,714,286 shares at $3.50 per share
- Gross proceeds of approximately $20.0 million ($23.0 million if option exercised)
- Underwriters granted 30-day option to purchase up to 857,142 additional shares
- Offering expected to close June 4, 2026
- Proceeds for working capital and general corporate purposes
- BTIG, LLC is lead bookrunning manager; Lucid Capital Markets is joint bookrunning manager
- Offering made under effective shelf registration statement on Form S-3 (File No. 333-288205)
Financial Impact
~$20M gross proceeds from sale of ~5.7M shares, representing approximately 11% dilution based on pre-offering share count (implied by market cap of $167M and price of $3.50 = ~47.7M shares pre-offering).
Risk Factors
- Dilution of ~11% for existing shareholders
- Proceeds used for working capital, not specific pipeline milestone, signaling potential cash burn concerns
- Clinical-stage biopharma with no approved products; regulatory setbacks could severely impact valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.35 $3.16 | ▼ −5.67% | ▼ −8.24% | $2.90 (−13.28%) |
Sep 14, 2026 18d ago | 8-K | $3.49 $3.29 | ▼ −5.73% | ▼ −5.84% | $2.90 (−16.76%) |
Aug 17, 2026 6w ago | 8-K | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 17, 2026 6w ago | Press Release | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 7, 2026 8w ago | 8-K | $3.58 $3.27 | ▼ −8.66% | ▼ −9.06% | $2.90 (−18.85%) |
Jul 22, 2026 10w ago | 8-K | $4.48 $3.23 | ▼ −27.90% | ▼ −25.50% | $2.90 (−35.16%) |
Jun 22, 2026 14w ago | Press Release | $3.90 $3.73 | ▼ −4.36% | ▼ −2.29% | $2.90 (−25.51%) |
Jun 5, 2026 17w ago | Press Release | $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $2.90 (−29.83%) |
Jun 4, 2026 17w ago | Press Release | $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $2.90 (+29.83%) |
Jun 3, 2026 17w ago | Press Release | $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $2.90 (+28.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access